Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2006

View Archived Issues

Free radical scavenging activity of nanoceria particles protects against retinal degeneration

Phase II study for epinastine nasal spray in treatment of seasonal allergic rhinitis

MLN-518 plus chemotherapy feasible in acute myelogenous leukemia

DanioLabs reports encouraging progress in Parkinson's disease programs

Targeting c-Kit with APCK-110 blocks AML cell proliferation in preclinical studies

Phase II trial set to begin for oral low-dose interferon alpha in HIV oral warts

ART-123 superior to heparin in disseminated intravascular coagulation

Snapshots of recent clinical trials in glioma: Part I

Substance isolated from greater celandine's extract shows antiretroviral activity

No statistical significance for nalmefene on endpoints in pathological gambling

Naproxcinod shows favorable 24-hour blood pressure profile

Preclinical profile of ABT-263: Abbott's novel Bcl-2 inhibitor

Erythropoietin benefits amyotrophic lateral sclerosis patients

TRO-19622 well tolerated at doses expected to be effective

Responses to oblimersen/fludarabine/cyclophosphamide evaluated in CLL study

Early phase I results with bortezomib and samarium Sm-153 lexidronam reported

ESPRIT technology focus of new program in Duchenne muscular dystrophy

Generx to advance to phase III for myocardial ischemia

Avastin plus interferon therapy improves PFS in metastatic renal cell carcinoma

Innovive acquires North American rights to tamibarotene

Intercell completes phase II trial for therapeutic hepatitis C vaccine IC-41

MethylGene selects MGCD-265 from c-MET kinase program

MGCD-0103 studied in new phase II trial in high-risk MDS and AML

Advexin therapy shows survival benefit in patients with abnormal p53 function

Phase IIb study evaluating Onyvax-P in hormone-resistant prostate cancer

Protherics to acquire MacroMed

Novel therapeutic agents for hepatitis C virus infection disclosed in recent patent literature

Otsuka and Chugai to copromote Pletaal in Japan

Recent patents impart new therapeutic agents for cancer

CytoGenix's synDNA vaccine against HIV shows activity in monkeys

Abilify Injection now available

EvaMist NDA accepted for review

Phase II trial under way for GV-1001 in NSCLC

Preminent tablet launched in Japan

MuGard receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...